blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Company profile
Ticker
BPMC
Exchange
Website
CEO
Jeffrey Albers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Blueprint Medicines Security Corporation • Blueprint Medicines (Switzerland) GmbH • Blueprint Medicines (Netherlands) B.V. • Blueprint Medicines (UK) Ltd. • Blueprint Medicines (Germany) GmbH • Blueprint Medicines Spain, S.L. • Blueprint Medicines (France) SAS • Blueprint Medicines (Italy) S.r.L. ...
BPMC stock data
Latest filings (excl ownership)
8-K
Other Events
22 Feb 24
S-8
Registration of securities for employees
16 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 24
8-K
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Blueprint Medicines Reports Third Quarter 2023 Results
26 Oct 23
8-K
Other Events
25 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Blueprint Medicines Reports Second Quarter 2023 Results
2 Aug 23
Transcripts
BPMC
Earnings call transcript
2023 Q4
15 Feb 24
BPMC
Earnings call transcript
2023 Q3
26 Oct 23
BPMC
Earnings call transcript
2023 Q2
2 Aug 23
BPMC
Earnings call transcript
2023 Q2
2 Aug 23
BPMC
Earnings call transcript
2023 Q1
4 May 23
BPMC
Earnings call transcript
2022 Q4
16 Feb 23
BPMC
Earnings call transcript
2022 Q2
2 Aug 22
BPMC
Earnings call transcript
2022 Q1
3 May 22
BPMC
Earnings call transcript
2021 Q4
16 Feb 22
BPMC
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
Jeffrey W. Albers
26 Mar 24
4
Jeffrey W. Albers
22 Mar 24
4
Michael Landsittel
19 Mar 24
4
Ariel Hurley
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Philina Lee
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
L. Becker Hewes
11 Mar 24
4
Debra Durso-Bumpus
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm |
Cash burn (monthly) | 5.40 mm | 19.25 mm | 44.51 mm | 46.06 mm | 34.83 mm | 39.94 mm |
Cash used (since last report) | 32.21 mm | 114.72 mm | 265.27 mm | 274.56 mm | 207.59 mm | 238.08 mm |
Cash remaining | 33.46 mm | -49.05 mm | -199.60 mm | -208.89 mm | -141.92 mm | -172.41 mm |
Runway (months of cash) | 6.2 | -2.5 | -4.5 | -4.5 | -4.1 | -4.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 217 |
Opened positions | 26 |
Closed positions | 31 |
Increased positions | 95 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 3.21 tn |
Total shares | 64.97 mm |
Total puts | 445.41 k |
Total calls | 181.75 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.59 mm | $330.84 bn |
FMR | 6.09 mm | $305.60 bn |
Vanguard | 5.97 mm | $299.67 bn |
T. Rowe Price | 5.50 mm | $275.85 bn |
Wellington Management | 5.08 mm | $255.14 bn |
Rock Springs Capital Management | 2.69 mm | $134.86 bn |
STT State Street | 2.63 mm | $131.86 bn |
T. Rowe Price Investment Management | 2.46 mm | $123.36 bn |
JPM JPMorgan Chase & Co. | 1.69 mm | $85.08 bn |
MCQEF Macquarie | 1.58 mm | $79.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 89.12 | 1,367 | 121.83 k | 176,050 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 88.6 | 6,285 | 556.85 k | 177,417 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 87.26 | 8,440 | 736.47 k | 183,702 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 86.46 | 6,251 | 540.46 k | 192,142 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 85.22 | 2,730 | 232.65 k | 198,393 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Option exercise | Acquire M | No | Yes | 15.01 | 10,000 | 150.10 k | 201,123 |
20 Mar 24 | Jeffrey W. Albers | Common Stock | Option exercise | Acquire M | No | Yes | 1.87 | 15,073 | 28.19 k | 191,123 |
20 Mar 24 | Jeffrey W. Albers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 15.01 | 10,000 | 150.10 k | 0 |
20 Mar 24 | Jeffrey W. Albers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 1.87 | 15,073 | 28.19 k | 0 |
15 Mar 24 | Michael Landsittel | Common Stock | Sell | Dispose S | No | Yes | 88.94 | 2,467 | 219.41 k | 47,286 |
News
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
26 Feb 24
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy And Safety Data And Advances In Mast Cell Disease Research At 2024 AAAAI Annual Meeting
23 Feb 24
Rigel Pharmaceuticals Acquires U.S. Rights To GAVRETO From Blueprint Medicines; Blueprint Receives $15M Purchase Price; Eligible For Up To $97.5M In Commercial Milestone Payments And $5M In Future Regulatory Milestone Payments
22 Feb 24
(BPMC) - Analyzing Blueprint Medicines's Short Interest
20 Feb 24
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
16 Feb 24
Press releases
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
23 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
15 Feb 24
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Feb 24
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
1 Feb 24